Perinatal aspects of inherited thrombophilia
- PMID: 10625206
- DOI: 10.1055/s-2007-994954
Perinatal aspects of inherited thrombophilia
Abstract
The identified main causes of inherited thrombophilia are deficiencies of antithrombin, protein C and protein S, activated protein C (APC) resistance and the factor V Leiden mutation, mutant factor II, and inherited hyperhomocysteinemia. In women from symptomatic families these defects may be associated with an increased risk of venous thrombosis in pregnancy and recurrent fetal loss. Inherited thrombophilia is common and appears to be a multigene disorder. The thrombotic risk would seem to be greatest in women with antithrombin deficiency and more than one thrombophilia defect. The abnormalities that are now recognized represent only part of the genetic predisposition to thrombosis. In assessing thrombotic risk in pregnancy, acquired risk factors as well as genetic predisposition should be considered. Increasing age, obesity, immobility, and delivery by cesarean section are major risk factors. Pregnancy should be planned, and each patient should be managed on an individual basis. In pregnancy, heparin is the anticoagulant of choice, and as far as possible, treatment with warfarin should be avoided because of the risks to the fetus. When patients are on long-term treatment with warfarin, pregnancy should be avoided, and warfarin should be discontinued prior to embarking on a pregnancy or as soon as pregnancy is suspected and before 6 weeks' gestation. In women from symptomatic families with antithrombin deficiency, adjusted dose heparin throughout pregnancy is recommended and warfarin for at least 3 months post partum. In protein C and protein S deficiency, factor V Leiden, or mutant factor II, treatment can be based on personal and family history. Thromboprophylaxis in late pregnancy and post partum should be considered. Fetal loss may be increased in women with inherited thrombophilia. The risk appears greatest in women with antithrombin deficiency and women with more than one thrombophilia defect. A number of reports have claimed that prophylactic treatment with heparin during pregnancy has resulted in successful pregnancy in women with recurrent fetal death and inherited thrombophilia.
Similar articles
-
Inherited thrombophilia and pregnancy: the obstetric perspective.Semin Thromb Hemost. 1998;24 Suppl 1:49-53. Semin Thromb Hemost. 1998. PMID: 9840692 Review.
-
Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium.Thromb Haemost. 2002 May;87(5):791-5. Thromb Haemost. 2002. PMID: 12038778
-
Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women.Br J Haematol. 2007 Feb;136(4):656-61. doi: 10.1111/j.1365-2141.2006.06480.x. Br J Haematol. 2007. PMID: 17223916 Clinical Trial.
-
Incidence of venous thromboembolism in families with inherited thrombophilia.Thromb Haemost. 1999 Feb;81(2):198-202. Thromb Haemost. 1999. PMID: 10063991
-
[Thrombophilia, preeclampsia and other pregnancy complications].Acta Med Croatica. 2009 Oct;63(4):297-305. Acta Med Croatica. 2009. PMID: 20034330 Review. Croatian.
Cited by
-
The effect of factor V Leiden carriage on maternal and fetal health.CMAJ. 2002 Jul 9;167(1):48-54. CMAJ. 2002. PMID: 12137081 Free PMC article. Review.
-
Congenital thrombophilia associated to obstetric complications.J Thromb Thrombolysis. 2002 Oct;14(2):163-9. doi: 10.1023/a:1023293114529. J Thromb Thrombolysis. 2002. PMID: 12714837 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources